22 April 2021>: Articles
Breakthrough Bleeding Episodes at Minimum and Improvement in Quality of Life in a Child with Severe Hemophilia A with Inhibitors Treated with Emicizumab: A Case Report from Chile
Rare diseaseViviana Abarca-Villaseca A* , Verónica Soto-Arellano A
Am J Case Rep 2021; 22:e929598
Table 2. Direct costs.
|Costs (USD)||1 year before emicizumab||1 year after emicizumab||Variation|
|Job opportunity cost||11,839||0||−100.0%|
|Medication cost as percentage of total cost||97.7%||99.6%|